Boehringer Ingelheim Press Releases

Boehringer Ingelheim's oral hepatitis C protease inhibitor and polymerase inhibitor combination shows rapid viral response without use of pegylated interferon

Heinrich Wieland Prize goes to scientist for work on key structures in human fatty acid synthesis

PRADAX™ (dabigatran etexilate) gains approval in Canada for stroke prevention in atrial fibrillation

Boehringer Ingelheim and MacroGenics Announce Global Alliance to Discover, Develop and Commercialize DART™-Based Antibody Therapeutics

US FDA Approves Pradaxa® (dabigatran etexilate) – a breakthrough treatment for stroke risk reduction in non-valvular atrial fibrillation

European Medicines Agency approves TWYNSTA® (telmisartan plus amlodipine) a new single pill combination that delivers powerful and consistent blood pressure reductions throughout 24 hours

Afatinib (BIBW 2992*) triples progression free survival in phase III study in lung cancer patients

Following regulatory feedback Boehringer Ingelheim decides to discontinue flibanserin development

Boehringer Ingelheim lays the foundations in Hanover for its European Veterinary Research Center

Boehringer Ingelheim microParts inaugurates new inhaler factory

Boehringer Ingelheim microParts inaugurates new inhaler factory

New phase III data further support the safety and efficacy profile of Boehringer Ingelheim’s investigational drug linagliptin

ERS COPD Research Award 2010
Sponsored by Boehringer Ingelheim

FDA Committee Unanimously Recommends Approval of Dabigatran Etexilate for Stroke Prevention in Atrial Fibrillation

Boehringer Ingelheim Initiates Phase III Clinical Trial with Novel Oral Agent in Advanced Breast Cancer

HIV-1 patients with an undetectable viral load can switch to VIRAMUNE® regardless of their CD4 count

Combination therapy of telmisartan and amlodipine provides significantly better blood pressure lowering than either agent alone

A new era for patients with atrial fibrillation - Dabigatran etexilate at the forefront